Article
Oncology
Cihan Erol, Mehmet Ali Nahit, Sendur Bulent Yalein
Summary: We report a case of actinomycosis infection possibly caused by bevacizumab treatment. The patient developed actinomycosis lesions after maintenance therapy with bevacizumab following chemotherapy.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Zi-Xian Liao, Ivan M. Kempson, Chia-Chen Hsieh, S-Ja Tseng, Pan-Chyr Yang
Summary: The presence of lactate and its relationship with drug resistance and genetic mutations in NSCLC highlights the potential for improving therapeutic outcomes by enzymatically lowering lactate levels. Targeting lactate may promote an oncolytic immune microenvironment within the tumor, offering a promising approach for enhancing NSCLC treatment efficacy.
DRUG DISCOVERY TODAY
(2021)
Review
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Xavier Quantin, Catherine Alix-Panabieres
Summary: This study discusses the application of immune checkpoint inhibitors in the treatment of metastatic nonsmall cell lung cancer and focuses on the evaluation of blood biomarkers such as circulating cell-free DNA, circulating tumor DNA, blood tumor mutational burden, and circulating tumor cells. Monitoring these biomarkers during immunotherapy may assist clinicians in making therapeutic decisions.
CLINICAL CHEMISTRY
(2023)
Article
Oncology
Brittney Chau, Philip H. G. Ituarte, Ashwin Shinde, Richard Li, Jessica Vazquez, Scott Glaser, Erminia Massarelli, Ravi Salgia, Loretta Erhunmwunsee, Kimlin Ashing, Arya Amini
Summary: The study found that foreign-born NSCLC patients in California have a lower risk of mortality compared to native-born patients after adjusting for treatments received and socioeconomic factors.
Review
Oncology
Kit Yee Wong, Alvin Ho-Kwan Cheung, Bonan Chen, Wai Nok Chan, Jun Yu, Kwok Wai Lo, Wei Kang, Ka Fai To
Summary: Lung cancer is a common and deadly disease, with the tumor microenvironment playing a crucial role. Cancer-associated fibroblasts (CAFs) have gained attention in the study of nonsmall cell lung carcinoma (NSCLC), as their heterogeneity and functions are closely associated with tumor development.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Respiratory System
Rudolf M. Huber, Diego Kauffmann-Guerrero, Hans Hoffmann, Michael Flentje
Summary: Recent developments in the treatment of locally advanced nonsmall cell lung cancer have focused on integrating immunotherapy with radiotherapy, chemotherapy, and adjuvant targeted therapy. The importance of consolidation therapy, pathological evaluation, and investigation of immunological features and driver mutations in improving management and prognosis has been emphasized.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Chemistry, Multidisciplinary
Elham Hatami, Prashanth K. B. Nagesh, Mohammed Sikander, Anupam Dhasmana, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu
Summary: The study demonstrates that Tannic acid (TA) has antiproliferative and antiangiogenic effects against nonsmall-cell lung cancer (NSCLC).
Article
Oncology
Jie Zhang, Di Wu, Ziran Zhang, Jieran Long, Guangming Tian, Yang Wang, Xiangjuan Ma, Xiaoling Chen, Jindi Han, Weiheng Hu, Ling Dai, Jun Nie, Jian Fang
Summary: The study evaluated the response and complications of patients with advanced NSCLC treated with pembrolizumab or bevacizumab plus chemotherapy. Results showed no significant differences between the two groups in terms of progression-free survival, overall survival, objective response rate, disease control rate, and adverse events.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Respiratory System
Florian Eichhorn, Hauke Winter
Summary: Patients with oligometastatic lung cancer, defined as having limited metastatic disease, may have better prognosis when treated with local ablative therapy for all lesions. In such cases, surgery and radiotherapy play a dominant role in the treatment course, offering a potentially curative local therapy in combination with systemic treatment based on interdisciplinary decisions.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Medicine, General & Internal
Jianfei Zhu, Zhenzhen Li, Jie Chen, Wensheng Li, Hongtao Wang, Tao Jiang, Yu Ma
Summary: FOXP3 is highly expressed in non-small cell lung cancer (NSCLC) and mainly expressed in regulatory T cells. High FOXP3 expression is associated with infiltration of malignant cells and poor survival rate. FOXP3 is involved in multiple signaling pathways, particularly the T cell receptor signaling pathway and Jak-STAT signaling pathway. FOXP3 may promote the malignant progression of NSCLC through regulation of T cell infiltration.
Review
Biotechnology & Applied Microbiology
Andrzej Jachowski, Mikolaj Marcinkowski, Jakub Szydlowski, Oskar Grabarczyk, Zuzanna Nogaj, Laz Marcin, Andrzej Plawski, Pawel Piotr Jagodzinski, Bartosz Kazimierz Slowikowski
Summary: Lung cancer, especially nonsmall cell lung cancer (NSCLC), is a highly prevalent and deadly disease worldwide. The treatment for NSCLC has evolved from traditional approaches to more personalized and minimally invasive methods, improving efficacy and reducing side effects. This review discusses established modern approaches such as immunotherapy and targeted therapy, as well as experimental methods like CRISPR and nanoparticles, which offer promising outcomes and faster recovery time for patients.
JOURNAL OF APPLIED GENETICS
(2023)
Article
Oncology
Lisa A. Cannon-Albright, Craig C. Teerlink, Jeff Stevens, Julio C. Facelli, Shamus R. Carr, Kristina Allen-Brady, Sonam Puri, Joan E. Bailey-Wilson, Anthony M. Musolf, Wallace Akerley
Summary: A unique approach with rare resources was used to identify candidate variants predisposing to familial nonsquamous nonsmall-cell lung cancers (NSNSCLC). Variants were tested for association with lung cancer risk in UK Biobank. This unique study identified multiple candidate predisposition variants for NSNSCLC, including a rare variant in FGF5 that was significantly associated with lung cancer risk and that segregated with lung cancer in the two pedigrees in which it was observed.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Congcong Chen, Ning Xue, Kangshou Liu, Qiang He, Cong Wang, Yanguan Guo, Jiaxin Tian, Xinjian Liu, Yunlong Pan, Guo Chen
Summary: RRM2 is a crucial subunit of RNR in cancer cell proliferation. We identified USP12 as the deubiquitinase for RRM2 in NSCLC cells, and found that USP12 depletion caused DNA replication stress and inhibited tumor growth in vivo and in vitro. High expression of USP12 was associated with poor prognosis in NSCLC patients, suggesting it as a potential therapeutic target for NSCLC treatment.
MOLECULAR CARCINOGENESIS
(2023)
Article
Respiratory System
Martin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, Corinna Elender, Harald Schaefer, Maike de Wit, Ulrich Kaiser, Jens Kern, Martina Janicke, Lisa Spring, Stefan Zacharias, Anja Kaiser-Osterhues, Annika Groth, Annette Hipper, Gregor Zaun, Steffen Doerfel, Bjoern Gueldenzoph, Lothar Mueller, Jens Uhlig, Michael Thomas, Martin Sebastian, Wilfried E. E. Eberhardt
Summary: This study reported prognostic factors in 2082 patients with wild-type non-small cell lung cancer (NSCLC), including the number and location of metastatic organ systems and liver metastases. Patients with involvement of four or more organ systems and liver metastases had shorter overall survival (OS) and progression-free survival (PFS). Female gender and early clinical stage were associated with better prognosis. The study underscores the importance of understanding prognostic factors in NSCLC. Overall, it received a score of 8 out of 10 for its importance.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Environmental Sciences
Guoxiang Rong, Zhongjun Pan, Ming Ding, Lihui Wang
Summary: The study revealed that the expression of RNF168 is positively correlated with survival in lung adenocarcinoma patients but not in squamous cell carcinoma patients. RNF168 suppresses cancer stem cell traits in NSCLC cells by promoting the ubiquitination and degradation of RhoC, suggesting a potential therapeutic target for NSCLC treatment.
ENVIRONMENTAL TOXICOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sander Bach, Birgit M. M. Wever, Mark A. van de Wiel, Joris D. Veltman, Sayed M. S. Hashemi, Geert Kazemier, Idris Bahce, Renske D. M. Steenbergen
Summary: This study investigated the circadian variation of urinary cfDNA abundance and methylation levels of cancer-associated genes in NSCLC patients. It found that men had significantly lower cfDNA concentrations and the variability in cfDNA levels between and within subjects was comparable with an ICC of 0.49. The study also found that the reproducibility of methylation markers varied considerably, ranging from 0.14 to 0.74, emphasizing the importance of collecting multiple samples per patient to improve test reproducibility.
Article
Oncology
Juergen Wolf, Edward B. Garon, Harry J. M. Groen, Daniel S. W. Tan, Isabelle Gilloteau, Sylvie Le Mouhaer, Marcio Hampe, Can Cai, Andrea Chassot-Agostinho, Maria Reynolds, Bintu Sherif, Rebecca S. Heist
Summary: Capmatinib, a MET inhibitor, showed significant antitumour activity and manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC). This study reported the patient-reported outcomes (PROs) of capmatinib treatment, which demonstrated improvements in cough and quality of life (QoL) in these patients, supporting the use of capmatinib in METex14-mutated aNSCLC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, Lynette M. Sholl, Weiwei Shi, Joao Alessi, Alessio Cortellini, Claudia A. M. Fulgenzi, Patrizia Viola, David J. Pinato, Sayed Hashemi, Idris Bahce, Ilias Houda, Ezgi B. Ulas, Teodora Radonic, Juha P. Vayrynen, Elin Richardsen, Simin Jamaly, Sigve Andersen, Tom Donnem, Mark M. Awad, David J. Kwiatkowski
Summary: This study developed a machine-learning-based approach to evaluate the association between tumor-infiltrating lymphocytes (TILs) and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. The results showed that high levels of TILs were associated with ICI treatment response and could be used for patient selection and precision therapy guidance.
Article
Public, Environmental & Occupational Health
Grigory Sidorenkov, Ralph Stadhouders, Colin Jacobs, Firdaus A. A. Mohamed Hoesein, Hester A. Gietema, Kristiaan Nackaerts, Zaigham Saghir, Marjolein A. Heuvelmans, Hylke C. Donker, Joachim G. Aerts, Roel Vermeulen, Andre Uitterlinden, Virissa Lenters, Jeroen van Rooij, Cornelia Schaefer-Prokop, Harry J. M. Groen, Pim A. de Jong, Robin Cornelissen, Mathias Prokop, Geertruida H. de Bock, Rozemarijn Vliegenthart
Summary: Trials have shown that low-dose computed tomography (CT) lung cancer screening can reduce lung cancer mortality in long-term (ex-)smokers, although many individuals have been subjected to unnecessary diagnostic procedures. This project aims to improve the efficiency of lung cancer screening by identifying high-risk participants and improving risk discrimination for nodules. The study will gather new data on genetics, air pollution, malignancy risk for lung nodules, and CT biomarkers beyond lung nodules, and develop prediction models for pre-screening and post-baseline-screening participant selection and nodule management.
EUROPEAN JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Oncology
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson
Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
H. Kievit, M. B. Muntinghe-Wagenaar, L. B. M. Hijmering-Kappelle, B. I. Hiddinga, J. F. Ubbels, R. Wijsman, G. Slingers, R. de Vries, H. J. M. Groen, H. A. M. Kerstjens, A. J. van der Wekken, T. J. N. Hiltermann
Summary: This study evaluates the safety and tolerability of Stereotactic radiotherapy combined with double Immune Checkpoint Inhibition (SICI) in advanced non-small cell lung cancer patients. The combination of SBRT and double immunotherapy is shown to be safe and feasible.
Article
Oncology
Haiyan Zeng, Lizza E. L. Hendriks, Willem J. A. Witlox, Harry J. M. Groen, Anne-Marie C. Dingemans, John Praag, Jose Belderbos, Ruud Houben, Vincent van der Noort, Dirk K. M. De Ruysscher
Summary: The aim of this study was to identify risk factors for self-reported cognitive impairment in stage III non-small cell lung cancer (NSCLC) after radical treatment. Cognitive functioning was assessed at seven pre-specified time points using the EORTC-QLQ-C30. The results showed that baseline cognitive impairment was the most important risk factor for subsequent cognitive impairment in stage III NSCLC.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
H. C. Donker, B. van Es, M. Tamminga, G. A. Lunter, L. C. L. T. van Kempen, E. Schuuring, T. J. N. Hiltermann, H. J. M. Groen
Summary: By analyzing DNA mutations in pre-treatment tissue, researchers have identified specific mutational signatures that are associated with response to immunotherapy in advanced non-small cell lung cancer patients. This finding could potentially help select patients who are likely to benefit from immunotherapy.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Theodore S. Kapellos, Kevin Babler, Wataru Fujii, Christina Nalkurthi, Anna C. Schaar, Lorenzo Bonaguro, Tal Pecht, Izabela Galvao, Shobhit Agrawal, Adem Saglam, Erica Dudkin, Amit Frishberg, Elena de Domenico, Arik Horne, Chantal Donovan, Richard Y. Kim, David Gallego-Ortega, Tessa E. Gillett, Meshal Ansari, Jonas Schulte-Schrepping, Nina Offermann, Ignazio Antignano, Burcu Sivri, Wenying Lu, Mathew S. Eapen, Martina van Uelft, Collins Osei-Sarpong, Maarten van den Berge, Hylke C. Donker, Harry J. M. Groen, Sukhwinder S. Sohal, Johanna Klein, Tina Schreiber, Andreas Feisst, Ali Oender Yildirim, Herbert B. Schiller, Martijn C. Nawijn, Matthias Becker, Kristian Haendler, Marc Beyer, Melania Capasso, Thomas Ulas, Jan Hasenauer, Carmen Pizarro, Fabian J. Theis, Philip M. Hansbro, Dirk Skowasch, Joachim L. Schultze
Summary: Systemic inflammation is a characteristic feature of late-stage severe lung disease, while the molecular, functional, and phenotypic changes in peripheral immune cells in the early stages of the disease remain poorly understood. In this study, using single-cell analyses, the researchers found that blood neutrophils are already increased in early-stage COPD, and the changes in their molecular and functional states correlate with the decline of lung function. Further investigation using a murine cigarette smoke exposure model revealed similar molecular changes in blood neutrophils and precursor populations in the blood and lung. The findings suggest that systemic molecular alterations in neutrophils and their precursors are present in the early stages of COPD, and may serve as potential therapeutic targets and biomarkers for early diagnosis and patient stratification.
Review
Oncology
Fenneke Zwierenga, Bianca A. M. H. van Veggel, Anke Van den Berg, Harry J. M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E. F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. Van der Wekken
Summary: This article provides a comprehensive assessment of drug sensitivity in vitro and in clinical settings for EGFRex20+ mutations in NSCLC. The activating A763_Y764insFQEA mutation shows better tumor response compared to mutations in other regions, suggesting the need for different treatment approaches. Classification beyond exon-based categories is necessary due to marked differences in treatment responses among EGFRex20+ mutations.
CANCER TREATMENT REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Paul van der Leest, Melanie Janning, Naomi Rifaela, Maria L. Aguirre Azpurua, Jolanthe Kropidlowski, Sonja Loges, Nicolas Lozano, Alexander Sartori, Darryl Irwin, Pierre-Jean Lamy, T. Jeroen N. Hiltermann, Harry J. M. Groen, Klaus Pantel, Leon C. van Kempen, Harriet Wikman, Ed Schuuring
Summary: Analysis of ctDNA using a suitable diagnostic-grade platform can guide treatment decisions and monitor disease progression in cancer patients. This multicenter study evaluated the use of UltraSEEK(R) Lung Panel and MassARRAY(R) System for ccfDNA analysis in NSCLC patients, comparing it with ddPCR and tumor tissue NGS. The results showed high concordance between UltraSEEK(R) and ddPCR, as well as a correlation between ctDNA level decrease detected with UltraSEEK(R) and improved treatment outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne
Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu
Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
H. C. Donker, K. Cuppens, G. Froyen, H. J. M. Groen, T. J. N. Hiltermann, B. Maes, E. Schuuring, P. -J. Volders, G. A. Lunter, B. van Es
Summary: This study aims to investigate the reliability of using comprehensive targeted sequencing to predict the efficacy of immune checkpoint inhibition (ICI) in non-small cell lung cancer (NSCLC). Somatic mutations of 126 patients were analyzed using panel-based sequencing of 523 cancer-related genes, and in silico simulations were performed on a separate dataset of 101 whole genome sequenced patients. The results suggest that current targeted panel sequencing is not reliable enough to predict ICI efficacy, and whole exome or genome sequencing should be used for downstream classification tasks in NSCLC.
Review
Radiology, Nuclear Medicine & Medical Imaging
Yifei Mao, Jiali Cai, Marjolein A. Heuvelmans, Rozemarijn Vliegenthart, Harry J. M. Groen, Matthijs Oudkerk, Marleen Vonder, Monique D. Dorrius, Geertruida H. de Bock
Summary: This systematic review and meta-analysis evaluated the performance of Lung-RADS (versions 1.0 and 1.1) in detecting lung cancer in different populations. The results showed that studies in high-risk populations had higher sensitivity and lower specificity than studies in general populations. Non-Asian studies tended to have better diagnostic performance than Asian studies. Limited evidence was available for the performance of Lung-RADS version 1.1 and its applicability to Asian populations.
EUROPEAN RADIOLOGY
(2023)